What is BPC-157?

Compound Spotlight

BPC-157 is fifteen amino acids long and has one of the largest animal literatures of any peptide in this catalog. It also has one of the narrowest: most of that literature comes from a single laboratory, and almost none of it involves people. Both facts belong in any honest description of the compound.

Where it comes from

The story starts in the early 1990s with the pharmacology department at the University of Zagreb. Sikiric and colleagues reported isolating a new peptide from gastric juice with a molecular mass of about 40,000, which they named BPC, for “body protection compound.” They proposed that the stomach mounts a protective counter-response to stress, and that BPC was one of its mediators.

BPC-157 is not that 40 kDa protein. It is a 15-amino-acid fragment of it, which the group described as essential for the parent’s activity and then characterized and synthesized on its own. Independent papers describe it the same way. What researchers handle today is a synthetic peptide, not something extracted from the stomach.

Proposed mechanisms

Most compounds in this catalog have a defined receptor. BPC-157 does not. The literature describes several pathways instead, and two of the clearest mechanistic papers come from outside Zagreb, at Chang Gung University in Taiwan.

Angiogenesis via VEGFR2. Hsieh and colleagues reported that BPC-157 increased vessel density in a chick embryo membrane assay and in endothelial tube-formation assays, and sped the return of blood flow in rats with hind-limb ischemia. In cultured human endothelial cells it increased expression of VEGF receptor 2 (but not VEGF itself), promoted the receptor’s internalization, and activated the VEGFR2-Akt-eNOS pathway, the route by which endothelial cells produce nitric oxide.

Cell migration via FAK-paxillin. In an earlier study the same institution cultured fibroblasts from rat Achilles tendon. BPC-157 did not make the cells proliferate faster, but it increased their outgrowth from tendon explants, their survival under oxidative stress, and their migration, alongside increased F-actin formation and phosphorylation of focal adhesion kinase and paxillin, two proteins that coordinate cell adhesion and movement.

The Zagreb group’s own reviews add further proposed links, including the Egr-1 and JAK-2 pathways and effects on serotonergic and dopaminergic systems. Treat these as hypotheses under investigation rather than a settled mechanism.

What research has examined

The range of models is wide. Reviews describe rodent studies of gut lesions, liver and pancreas injury, tendon, ligament, muscle and bone injury, nerve transection and spinal cord compression. A 2025 systematic review from an orthopaedic perspective screened 544 records and included 36 studies relevant to musculoskeletal use: 35 preclinical and one clinical. In the preclinical models, BPC-157 was reported to improve functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injury.

That same review reported that the preclinical literature describes hepatic metabolism, renal clearance and a half-life under 30 minutes, and that no clinical safety data were found.

What the evidence supports

Two structural problems run through this literature, and they matter more than any single finding.

One research group. The BPC-157 literature is overwhelmingly the work of one team. A PubMed search for BPC-157 in titles and abstracts returns about 226 records, of which about 174 list Sikiric as an author. The work is peer reviewed and internally consistent, but a 2019 review from Loughborough University noted that only a handful of research groups have studied the peptide in depth. Independent replication, such as the Taiwanese mechanistic work, exists but is thin.

Almost no human data. A 2025 narrative review counted three human pilot studies in total: a retrospective report on knee pain, a study in interstitial cystitis, and an intravenous study with two participants. None was randomized or placebo controlled. The same reviewers concluded that BPC-157 should be considered investigational. A handful of uncontrolled reports cannot establish efficacy or safety.

The angiogenesis mechanism carries a caveat worth stating. Promoting new blood vessel growth is what makes BPC-157 plausible as a repair compound in poorly vascularized tissue like tendon. It is also a process tumors depend on, and whether that matters in practice has not been studied in people.

On regulation: BPC-157 is not approved for human use by the FDA or any other regulator. WADA names it on the 2026 Prohibited List under S0, non-approved substances, prohibited at all times. The FDA’s list of bulk drug substances that may present significant safety risks in compounding cites immunogenicity and peptide-impurity concerns for BPC-157, and records it as previously in Category 2 with the nomination later withdrawn. Check the FDA page directly for its current status.

Frequently asked questions

Is BPC-157 found naturally in the body?

Its parent protein, BPC, was reported in human gastric juice. BPC-157 is a synthetic 15-amino-acid fragment of that protein.

Why is almost all the research from one group?

The Zagreb group identified the compound and has studied it for more than three decades, so it had a long head start. Why so few outside laboratories have followed is not something the published literature settles. Whatever the reason, a long publication record from one team is not a substitute for independent replication.

How is it related to TB-500?

Only by research interest. The two are unrelated peptides with different origins and proposed mechanisms, and they are often discussed together in tissue-repair research. Our Wolverine Blend breakdown covers both.

How do I know what is actually in the vial?

Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Lot numbers on the vial should match the COA you are referencing.

References

• Sikirić P, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313–327.
• Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857–865.
• Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780.
• Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333.
• Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159.
• Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495.
• Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20–24.
• McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611–619.

View the BPC-157 product listing →

Read our Wolverine Blend (BPC-157 and TB-500) breakdown →

Read our GLOW Blend breakdown →

Look up your lot Certificate of Analysis →

For laboratory and research use only. Not for human consumption. BPC-157 has no controlled human clinical trial data, is not approved by any regulatory authority, and is prohibited by WADA. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.

Related research compounds

Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:

• BPC-157

For laboratory research use only. Not for human consumption.